Related Experiment Videos

Transcriptome profiling and network analysis of genetically hypertensive mice identifies potential pharmacological

Oscar Puig1, I-Ming Wang, Ping Cheng

  • 1Department of Molecular Profiling Research Informatics, Merck Research Laboratories, Rahway, New Jersey 07065, USA.

Physiological Genomics
|July 1, 2010
PubMed

Insights

Researchers identified new biological pathways regulating blood pressure using genetically hypertensive, normotensive, and hypotensive mouse models. This study offers novel gene targets for hypertension treatment.

Area of Science:

  • Genetics
  • Cardiovascular Science
  • Pharmacology

Background:

  • Hypertension affects nearly a billion people globally, leading to severe cardiovascular and renal complications.
  • Limited validated gene targets exist for effective pharmacological hypertension treatment.
  • Novel biological pathways and therapeutic targets are needed to manage blood pressure.

Purpose of the Study:

  • To identify novel biological pathways and gene targets for hypertension treatment.
  • To analyze gene expression differences in mouse models with varying blood pressure levels.
  • To discover potential therapeutic targets for pharmacological intervention.

Main Methods:

  • Gene expression profiling was conducted in the liver, heart, kidney, and aorta of three inbred mouse strains: BPH (hypertensive), BPN (normotensive), and BPL (hypotensive).
  • Organ-specific gene expression signatures were analyzed for enriched biological processes.
  • Genetic Bayesian networks were integrated with phenotype-associated genes to differentiate causal genes from consequential genes in the kidney.

Main Results:

  • Multiple biological pathways associated with blood pressure phenotypes were identified.
  • These pathways represent a source of candidate genes potentially causal for hypertension.
  • The study successfully distinguished genes whose expression changes may cause blood pressure alterations from those affected by blood pressure changes in the kidney.

Conclusions:

  • The integration of gene expression profiling and genetic network analysis is a powerful strategy for identifying novel hypertension targets.
  • This research provides a foundation for discovering new pharmacological treatments for hypertension.
  • The identified pathways and genes offer promising avenues for future therapeutic development in managing blood pressure.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...